GSS
GENETIC SIGNATURES LIMITED
$0.0760
0.00%
Trading halt
Market cap
$17M
Turnover
—
Last price
$0.0760
Day change
0.00%
Announcements
15
Range, past year
Open 0.295 · Low 0.051 · Now 0.076 · High 0.690
Open GSS in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
GSS momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
21/100
Wyckoff phase
Downtrend15d
Trend stage
Breakdown
1 Day
+0.0%
1 Week
+11.8%
1 Month
-5.0%
1 Year
-73.8%
RSI
48
Avg daily range
5.8%
GENETIC SIGNATURES LIMITED scores 21 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 15 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently matching and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -28.4%
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsGSS announcements
Recent price-sensitive releases.
- 2026-11-16 Trading Halt Trading Halt
- 2026-11-13 TOV: GSS - Panel Receives Application Scheme of Arrangement | Takeover - Other
- 2026-10-21 Update on Commercial Terms for the Proposed Merger with MAP Scheme of Arrangement
- 2026-10-08 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-09-22 GSS Investor Presentation - Proposed Merger with MAP Company Presentation
- 2026-09-22 GSS and MAP agree to Commercial Terms for Merger Scheme of Arrangement | Takeover - Timer Applied
- 2026-09-17 Receipt of Section 249D Notice from BCAL Diagnostics Notice of Meeting - Other
More Health Care stocks
Most traded in the same sector.